Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma

This study is comparing a new type of imaging scan using a radioactive tracer (89Zr-panitumumab) that targets cancer cells against the standard PET scan (using FDG) to better detect hidden lymph node involvement in patients with newly diagnosed head and neck squamous cell carcinoma. **You may be eligible if:** - You are 18 years or older - You have a biopsy-confirmed diagnosis of head and neck squamous cell carcinoma - You are newly diagnosed and scheduled for surgery with the goal of cure - Your lymph nodes appear normal on clinical exam and imaging (no suspected spread to lymph nodes) - Your blood counts, kidney function, and liver function are within acceptable ranges **You may NOT be eligible if:** - You have received an investigational drug within the past 30 days - You have had a heart attack, stroke, or unstable heart condition in the past 6 months - You have previously had surgery for head and neck squamous cell carcinoma - You have had allergic reactions to infused antibody therapies in the past - You are pregnant or breastfeeding - You are taking certain heart medications (Class I-A or III antiarrhythmics) Talk to your doctor to see if this trial is right for you.